American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time

References

• Centers for Disease Control and Prevention. Drug overdose deaths remained high in 2021 [Internet]. 2023 [cited 2023 Sep 18]. https://www.cdc.gov/drugoverdose/deaths/index.html.
   Google Scholar
• Harris E. FDA approves nalmefene, a longer-lasting opioid reversal nasal spray. JAMA. 2023;329(23):2012. doi:10.1001/jama.2023.9608.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Ohmeda Pharmaceutical Products Division, Inc. Investigational new drug approval letter for nalmefene hydrochloride injection (Revex®) [Internet]. 1995 [cited 2023 Sep 4]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020459Orig1s000rev.pdf.
   Google Scholar
• Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2022;233:108019. doi:10.1016/j.pharmthera.2021.108019.
   PubMed Web of Science ®Google Scholar
• Britch SC, Walsh SL. Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology. 2022;239(7):2063–2081. doi:10.1007/s00213-022-06125-5.
   PubMed Web of Science ®Google Scholar
• kaleo, inc. Naloxone Package Insert [Internet]. 2022 [cited 2023 Aug 17]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215457s000lbl.pdf.
   Google Scholar
• Krieter P, Gyaw S, Crystal R, et al. Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther. 2019;371(2):409–415. doi:10.1124/jpet.118.256115.
   PubMed Web of Science ®Google Scholar
• Purdue Pharmaceuticals LP. Nalmefene hydrochloride injection package insert [Internet]. 2021 [cited 2023 Jul 18]. https://www.accessdata.fda.gov/spl/data/d4bb0797-a4ed-4ed4-9904-604433eea4ff/d4bb0797-a4ed-4ed4-9904-604433eea4ff.xml.
   Google Scholar
• OPVEE® (nalmefene) nasal spray package insert [Internet]. www.opvee.com. 2023 [cited 2023 Jul 18]. https://opvee.com/wp-content/uploads/2023/07/Combined-USPI_Patient-Info_IFU_Clean_05July2023.pdf.
   Google Scholar
• Nalmefene returns for reversal of opioid overdose. Med Lett Drugs Ther. 2022;64:141–142.
   PubMed Web of Science ®Google Scholar
• Brescia-Oddo TL, Shibuya RB, Roca RA. NDA 217470 medical officer, cross-discipline team leader, and division director summary review [Internet]. U.S. Food and Drug Administration. 2023 [cited 2023 Oct 26]. https://www.fda.gov/media/171603/download.
   Google Scholar
• U.S. Food and Drug Administration. Nalmefene Hydrochloride Injection Abbreviated New Drug Application Approval [Internet]. 2022 [cited 2023 Jul 18]. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212955Orig1s000ltr.pdf.
   Google Scholar
• Department of Health and Human Services. Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base/milliliter and 1.0 milligram base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. Fed Regist. 2017;82:51282–51283.
   Google Scholar
• Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med. 1993;22(2):187–190. doi:10.1016/s0196-0644(05)80200-8.
   PubMed Web of Science ®Google Scholar
• Kaplan JL, Marx JA, Calabro JJ, et al. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med. 1999;34(1):42–50. doi:10.1016/s0196-0644(99)70270-2.
   PubMed Web of Science ®Google Scholar
• Gal TJ, DiFazio CA. Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology. 1986;64(2):175–180. doi:10.1097/00000542-198602000-00008.
   PubMed Web of Science ®Google Scholar
• Glass PS, Jhaveri RM, Smith LR. Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg. 1994;78(3):536–541. doi:10.1213/00000539-199403000-00021.
   PubMed Web of Science ®Google Scholar
• Cassel JA, Daubert JD, DeHaven RN. [(3)H]alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005;520(1-3):29–36. doi:10.1016/j.ejphar.2005.08.008.
   PubMed Web of Science ®Google Scholar
• Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63–88. doi:10.1177/2042098617744161.
   PubMed Web of Science ®Google Scholar
• Kim S, Wagner HN, Villemagne VL, et al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med. 1997;38(11):1726–1731.
   PubMed Web of Science ®Google Scholar
• Sutter ME, Gerona RR, Davis MT, et al. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017;24(1):106–113. doi:10.1111/acem.13034.
   PubMed Web of Science ®Google Scholar
• Klar SA, Brodkin E, Gibson E, et al. Notes from the field: furanyl-Fentanyl overdose events caused by smoking contaminated crack Cocaine – British Columbia, Canada, July 15-18, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(37):1015–1016. doi:10.15585/mmwr.mm6537a6.
   PubMed Web of Science ®Google Scholar
• Schumann H, Erickson T, Thompson TM, et al. Fentanyl epidemic in Chicago, Illinois and surrounding cook county. Clin Toxicol. 2008;46(6):501–506. doi:10.1080/15563650701877374.
   PubMed Web of Science ®Google Scholar
• Carpenter J, Murray BP, Atti S, et al. Naloxone dosing after opioid overdose in the era of illicitly manufactured fentanyl. J Med Toxicol. 2020;16(1):41–48. doi:10.1007/s13181-019-00735-w.
   PubMed Web of Science ®Google Scholar
• Lubman D, Koutsogiannis Z, Kronborg I. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users. Drug Alcohol Rev. 2003;22(4):433–436. doi:10.1080/09595230310001613958.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Weerts EM, Huhn AS, et al. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addict Biol. 2020;25:e12680.
   PubMed Web of Science ®Google Scholar
• Merrill J, Marshall R. Opioid detoxification using naloxone. Drug Alcohol Rev. 1997;16(1):3–6. doi:10.1080/09595239700186271.
   PubMed Web of Science ®Google Scholar
• Kunzler NM, Wightman RS, Nelson LS. Opioid withdrawal precipitated by long-acting antagonists. J Emerg Med. 2020;58(2):245–253. doi:10.1016/j.jemermed.2019.12.015.
   PubMed Web of Science ®Google Scholar